|
1
|
Thun MJ, DeLancey JO, Center MM, Jemal A
and Ward EM: The global burden of cancer: Priorities for
prevention. Carcinogenesis. 31:100–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold: ESMO Guidelines Working Group: Metastatic colorectal
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 25 Suppl 3:iii1–iii9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Cancer society, . Colorectal
cancer: What are the key statistics about colorectal cancer?
American cancer society website. http://www.cancer.org/Cancer/ColonandRectumCancer/DetailedGuide/colorectal-cancer-key-statisticsOctober
6–2015
|
|
4
|
Center for Cancer Control and Information
Services NCC, Japan Recent cancer statistics. 2014.http://ganjoho.jp/reg_stat/statistics/stat/summary.html03–August.
2016
|
|
5
|
Watanabe T, Itabashi M, Shimada Y, Tanaka
S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et
al: Japanese Society for Cancer of the Colon and Rectum (JSCCR)
Guidelines 2014 for treatment of colorectal cancer. Int J Clin
Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colvin H, Mizushima T, Eguchi H, et al:
Gastroenterological surgery in Japan: The past, the present and the
future. Ann Gastroenterol Surg. 1:5–10. 2017. View Article : Google Scholar
|
|
7
|
Ehnman M, Missiaglia E, Folestad E, Selfe
J, Strell C, Thway K, Brodin B, Pietras K, Shipley J, Östman A and
Eriksson U: Distinct effects of ligand-induced PDGFR α and PDGFRβ
signaling in the human rhabdomyosarcoma tumor cell and stroma cell
compartments. Cancer Res. 73:2139–2149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang P, Song L, Ge H, Jin P, Jiang Y, Hu W
and Geng N: Crenolanib, a PDGFR inhibitor, suppresses lung cancer
cell proliferation and inhibits tumor growth in vivo. Onco Targets
Ther. 7:1761–1768. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weissmueller S, Manchado E, Saborowski M,
Morris JP IV, Wagenblast E, Davis CA, Moon SH, Pfister NT,
Tschaharganeh DF, Kitzing T, et al: Mutant p53 drives pancreatic
cancer metastasis through cell-autonomous PDGF receptor β
signaling. Cell. 157:382–394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayashi Y, Bardsley MR, Toyomasu Y,
Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML,
Bingener-Casey J, Tang CM, et al: Platelet-derived growth factor
receptor-α regulates proliferation of gastrointestinal stromal
tumor cells with mutations in KIT by stabilizing ETV1.
Gastroenterology. 149:420–432.e16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Frödin M, Mezheyeuski A, Corvigno S,
Harmenberg U, Sandström P, Egevad L, Johansson M and Östman A:
Perivascular PDGFR- β is an independent marker for prognosis in
renal cell carcinoma. Br J Cancer. 116:195–201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mezheyeuski A, Lindh Bradic M, Guren TK,
Dragomir A, Pfeiffer P, Kure EH, Ikdahl T, Skovlund E, Corvigno S,
Strell C, et al: Survival-associated heterogeneity of
marker-defined perivascular cells in colorectal cancer. Oncotarget.
7:41948–41958. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Steller EJ, Raats DA, Koster J, Rutten B,
Govaert KM, Emmink BL, Snoeren N, van Hooff SR, Holstege FC, Maas
C, et al: PDGFRB promotes liver metastasis formation of
mesenchymal-like colorectal tumor cells. Neoplasia. 15:204–217.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith CC, Lasater EA, Lin KC, Wang Q,
McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M,
et al: Crenolanib is a selective type I pan-FLT3 inhibitor. Proc
Natl Acad Sci USA. 111:5319–5324. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo
F, Pierce KJ, Olszanski AJ and Cohen RB: Phase I study of the
safety, tolerability, and pharmacokinetics of oral CP-868,596, a
highly specific platelet-derived growth factor receptor tyrosine
kinase inhibitor in patients with advanced cancers. J Clin Oncol.
27:5262–5269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sobin LH GM and Wittekind C: TNM
Classification of Malignant Tumors. 7th. Wiley-Blackwell; Oxford:
2010
|
|
17
|
Corvigno S, Wisman GB, Mezheyeuski A, van
der Zee AG, Nijman HW, Åvall-Lundqvist E, Östman A and Dahlstrand
H: Markers of fibroblast-rich tumor stroma and perivascular cells
in serous ovarian cancer: Inter- and intra-patient heterogeneity
and impact on survival. Oncotarget. 7:18573–18584. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heinrich MC, Griffith D, McKinley A,
Patterson J, Presnell A, Ramachandran A and Debiec-Rychter M:
Crenolanib inhibits the drug-resistant PDGFRA D842V mutation
associated with imatinib-resistant gastrointestinal stromal tumors.
Clin Cancer Res. 18:4375–4384. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gril B, Palmieri D, Qian Y, Anwar T,
Liewehr DJ, Steinberg SM, Andreu Z, Masana D, Fernández P, Steeg PS
and Vidal-Vanaclocha F: Pazopanib inhibits the activation of
PDGFRβ-expressing astrocytes in the brain metastatic
microenvironment of breast cancer cells. Am J Pathol.
182:2368–2379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heske CM, Yeung C, Mendoza A, Baumgart JT,
Edessa LD, Wan X and Helman LJ: The role of PDGFR-β activation in
acquired resistance to IGF-1R blockade in preclinical models of
rhabdomyosarcoma. Transl Oncol. 9:540–547. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gotzmann J, Fischer AN, Zojer M, Mikula M,
Proell V, Huber H, Jechlinger M, Waerner T, Weith A, Beug H and
Mikulits W: A crucial function of PDGF in TGF-beta-mediated cancer
progression of hepatocytes. Oncogene. 25:3170–3185. 2006.
View Article : Google Scholar : PubMed/NCBI
|
